PEACE-1: Radiotherapy + abiraterone improves rPFS in low-volume de novo mCSPC but not OS. It reduces serious genitourinary events without increasing toxicity. A promising addition to standard care #ProstateCancer #Oncology #PEACE1 @oncoalert.bsky.social @bossial.bsky.social @apccc.bsky.social
November 22, 2024 at 8:03 AM
PEACE-1: Radiotherapy + abiraterone improves rPFS in low-volume de novo mCSPC but not OS. It reduces serious genitourinary events without increasing toxicity. A promising addition to standard care #ProstateCancer #Oncology #PEACE1 @oncoalert.bsky.social @bossial.bsky.social @apccc.bsky.social
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc
Dr Bilen on Real-World OS Benefit With Apalutamide vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
www.onclive.com
February 23, 2026 at 1:46 PM
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc
NEW from #ASCO25: AMPLITUDE research summary: Adding niraparib to standard treatment can help slow cancer growth for people with #mCSPC with HRR gene alterations ➡️ www.asco.org/practice-pat...
#PCSM #ProstateCancer
#PCSM #ProstateCancer
June 3, 2025 at 4:46 PM
NEW from #ASCO25: AMPLITUDE research summary: Adding niraparib to standard treatment can help slow cancer growth for people with #mCSPC with HRR gene alterations ➡️ www.asco.org/practice-pat...
#PCSM #ProstateCancer
#PCSM #ProstateCancer
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC from @neerajagarwal.bsky.social @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/t...
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC
The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...
myopenmedicine.com
July 6, 2026 at 4:25 PM
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC from @neerajagarwal.bsky.social @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/t...
Post hoc analysis of TITAN examined the association between achieving ultralow prostate-specific antigen (PSA) levels (≤0.2 ng/mL) and clinical outcomes in patients with metastatic castration-sensitive #ProstateCancer (mCSPC) treated with apalutamide.
https://buff.ly/3CJA5bO
https://buff.ly/3CJA5bO
November 19, 2024 at 2:20 PM
Post hoc analysis of TITAN examined the association between achieving ultralow prostate-specific antigen (PSA) levels (≤0.2 ng/mL) and clinical outcomes in patients with metastatic castration-sensitive #ProstateCancer (mCSPC) treated with apalutamide.
https://buff.ly/3CJA5bO
https://buff.ly/3CJA5bO
Most expected #Arches 5 yr follow up data to be pro-forma #ASCO25
@ascocancer.bsky.social
But then this data popped up 👀
Less clear benefit of Enza+ADT in low volume #mCSPC
Should this raise ?s for #mCSPC intensification w/#parp & #LU-psma
Implications for over treating PSMA+ recurrence?
@ascocancer.bsky.social
But then this data popped up 👀
Less clear benefit of Enza+ADT in low volume #mCSPC
Should this raise ?s for #mCSPC intensification w/#parp & #LU-psma
Implications for over treating PSMA+ recurrence?
June 4, 2025 at 2:59 AM
ust presented at #ASCO25: AMPLITUDE is the first trial to show improved rPFS in HRR-altered mCSPC w/combo PARPi + SOC. #ASCODailyNews has more on these practice-changing results: dailynews.ascopubs.org/do/amplitude... #GUCSM #prostatecancer
June 3, 2025 at 5:43 PM
ust presented at #ASCO25: AMPLITUDE is the first trial to show improved rPFS in HRR-altered mCSPC w/combo PARPi + SOC. #ASCODailyNews has more on these practice-changing results: dailynews.ascopubs.org/do/amplitude... #GUCSM #prostatecancer
📊 New real-world evidence:How do apalutamide and enzalutamide compare for PSA response in metastatic castration-sensitive prostate cancer?
This study provides important comparative insights to inform treatment decisions.
🔗 Read now: buff.ly/CsFU3XV
#ProstateCancer #Oncology #RealWorldEvidence #mCSPC
This study provides important comparative insights to inform treatment decisions.
🔗 Read now: buff.ly/CsFU3XV
#ProstateCancer #Oncology #RealWorldEvidence #mCSPC
June 6, 2026 at 7:02 AM
📊 New real-world evidence:How do apalutamide and enzalutamide compare for PSA response in metastatic castration-sensitive prostate cancer?
This study provides important comparative insights to inform treatment decisions.
🔗 Read now: buff.ly/CsFU3XV
#ProstateCancer #Oncology #RealWorldEvidence #mCSPC
This study provides important comparative insights to inform treatment decisions.
🔗 Read now: buff.ly/CsFU3XV
#ProstateCancer #Oncology #RealWorldEvidence #mCSPC
#PSMA+BCR
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
October 28, 2025 at 3:05 PM
#PSMA+BCR
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
🚨🧬 The FDA has granted Priority Review to talazoparib plus enzalutamide for patients with HRR-altered metastatic castration-sensitive prostate cancer (mCSPC).
Read more ➡️ www.onclive.com/view/fda-gra...
#ProstateCancer #mCSPC #GUonc #PARPInhibitors #PrecisionOncology #TargetedTherapy #Oncology
Read more ➡️ www.onclive.com/view/fda-gra...
#ProstateCancer #mCSPC #GUonc #PARPInhibitors #PrecisionOncology #TargetedTherapy #Oncology
FDA Grants Priority Review to Talazoparib Plus Enzalutamide in HRR-Altered mCSPC | OncLive
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
www.onclive.com
July 23, 2026 at 3:40 PM
🚨🧬 The FDA has granted Priority Review to talazoparib plus enzalutamide for patients with HRR-altered metastatic castration-sensitive prostate cancer (mCSPC).
Read more ➡️ www.onclive.com/view/fda-gra...
#ProstateCancer #mCSPC #GUonc #PARPInhibitors #PrecisionOncology #TargetedTherapy #Oncology
Read more ➡️ www.onclive.com/view/fda-gra...
#ProstateCancer #mCSPC #GUonc #PARPInhibitors #PrecisionOncology #TargetedTherapy #Oncology
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc
Dr Bilen on a Real-World Analysis of Apalutamide vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.
www.onclive.com
February 20, 2026 at 10:35 PM
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc
AMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in HRR-Altered mCSPC algorithm from @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/a...
AMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in HRR-Altered mCSPC
The algorithm is broadly aligned with current mCSPC practice for diagnosis, early treatment intensification with AR pathway inhibitors, and routine consideration of germline/somatic testing. However, ...
myopenmedicine.com
July 17, 2026 at 3:09 PM
AMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in HRR-Altered mCSPC algorithm from @drnataliagandur.bsky.social: myopenmedicine.com/algorithms/a...
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC from @neerajagarwal.bsky.social: myopenmedicine.com/algorithms/t...
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC
The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...
myopenmedicine.com
August 26, 2026 at 3:15 PM
TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC from @neerajagarwal.bsky.social: myopenmedicine.com/algorithms/t...
I was both under 90% and 0.20 ng/mL at 8 months. Now at a PSA of 0.088 per my last test. Gives fairly good odds for over 5 years or more before progression.
How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data
In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration-sensitive prostate cancer (mCSPC), achieving a prostate-specific antigen (PSA) of <0.2 ng/mL...
acsjournals.onlinelibrary.wiley.com
August 10, 2026 at 10:18 PM
I was both under 90% and 0.20 ng/mL at 8 months. Now at a PSA of 0.088 per my last test. Gives fairly good odds for over 5 years or more before progression.
Result never in doubt in #mCSPC #ProstateCancer given design
Questions should focus on short & long term toxicity. Also is sequencing (w/deferred tox) in any way inferior❓
Talazoparib/Enzalutamide Shows Improved Radiographic PFS
www.targetedonc.com/view/talazop...
Questions should focus on short & long term toxicity. Also is sequencing (w/deferred tox) in any way inferior❓
Talazoparib/Enzalutamide Shows Improved Radiographic PFS
www.targetedonc.com/view/talazop...
Talazoparib/Enzalutamide Shows Improved Radiographic PFS in Metastatic Castration-Sensitive Prostate Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated mCSPC, demonstrating that targeting DNA damage repair...
www.targetedonc.com
March 21, 2026 at 1:06 PM
Result never in doubt in #mCSPC #ProstateCancer given design
Questions should focus on short & long term toxicity. Also is sequencing (w/deferred tox) in any way inferior❓
Talazoparib/Enzalutamide Shows Improved Radiographic PFS
www.targetedonc.com/view/talazop...
Questions should focus on short & long term toxicity. Also is sequencing (w/deferred tox) in any way inferior❓
Talazoparib/Enzalutamide Shows Improved Radiographic PFS
www.targetedonc.com/view/talazop...
WATCH: Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC #AUA26 #pcsm #oncology
www.onclive.com/view/dr-scho...
www.onclive.com/view/dr-scho...
Dr Schoen on a Real-World Study of Enzalutamide vs Apalutamide in mCSPC | OncLive
Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.
www.onclive.com
May 18, 2026 at 8:28 PM
WATCH: Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC #AUA26 #pcsm #oncology
www.onclive.com/view/dr-scho...
www.onclive.com/view/dr-scho...
How deep should PSA go in mCSPC?
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
January 19, 2026 at 8:15 AM
How deep should PSA go in mCSPC?
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
Androgen deprivation + anti-PD1 trial for #prostatecancer.
"PRIME-CUT Phase II trial treating men with metastatic castration-sensitive prostate cancer with a combination of standard of care chemo-hormonal therapy & anti-PD-1 immunotherapy using the anti-PD-1 cemiplimab."
#immunology #immunotherapy
"PRIME-CUT Phase II trial treating men with metastatic castration-sensitive prostate cancer with a combination of standard of care chemo-hormonal therapy & anti-PD-1 immunotherapy using the anti-PD-1 cemiplimab."
#immunology #immunotherapy
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in meta...
TME composition of metastatic castration-sensitive prostate cancer (mCSPC) remains
elusive. Hawley et al. perform scRNA-seq analysis of metastatic sites from mCSPC patients
with ADT and anti-PD-1 tre...
www.cell.com
November 27, 2023 at 9:54 AM
Androgen deprivation + anti-PD1 trial for #prostatecancer.
"PRIME-CUT Phase II trial treating men with metastatic castration-sensitive prostate cancer with a combination of standard of care chemo-hormonal therapy & anti-PD-1 immunotherapy using the anti-PD-1 cemiplimab."
#immunology #immunotherapy
"PRIME-CUT Phase II trial treating men with metastatic castration-sensitive prostate cancer with a combination of standard of care chemo-hormonal therapy & anti-PD-1 immunotherapy using the anti-PD-1 cemiplimab."
#immunology #immunotherapy
FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer
@fda.gov
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Niraparib #Abiraterone #BRCA2 #ProstateCancer #MCSPC
@fda.gov
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Niraparib #Abiraterone #BRCA2 #ProstateCancer #MCSPC
FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer - OncoDaily
FDA approves niraparib plus abiraterone and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on AMPLITUDE trial data.
oncodaily.com
December 16, 2025 at 10:47 PM
FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer
@fda.gov
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Niraparib #Abiraterone #BRCA2 #ProstateCancer #MCSPC
@fda.gov
oncodaily.com/fda-approval...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Niraparib #Abiraterone #BRCA2 #ProstateCancer #MCSPC
PET PSMA refining patients classification mCSPC #prostatecancer
But what to do with it? Need for clinical trials. #APCCCDiagnostics25 @OncoAlert
But what to do with it? Need for clinical trials. #APCCCDiagnostics25 @OncoAlert
February 28, 2025 at 9:50 AM
PET PSMA refining patients classification mCSPC #prostatecancer
But what to do with it? Need for clinical trials. #APCCCDiagnostics25 @OncoAlert
But what to do with it? Need for clinical trials. #APCCCDiagnostics25 @OncoAlert
Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations @mskcancercenter.bsky.social #pcsm #oncology www.onclive.com/view/nirapar...
Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations | OncLive
The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.
www.onclive.com
October 14, 2025 at 2:08 PM
Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations @mskcancercenter.bsky.social #pcsm #oncology www.onclive.com/view/nirapar...
✨ #ASCO25 ✨
🚨BREAKING:
AMPLITUDE: First Phase 3 trial to show improved rPFS in HRR-altered mCSPC with PARP + AR-pathway inhibitor combo
🧬 Niraparib + AAP cut progression/death risk by 37%
🔍 Strongest benefit in BRCA-mutated cases
🔗 bit.ly/ONCOnews4J-7
#OncoAlert #OncEd #ONCOnews #ProstateCancer
🚨BREAKING:
AMPLITUDE: First Phase 3 trial to show improved rPFS in HRR-altered mCSPC with PARP + AR-pathway inhibitor combo
🧬 Niraparib + AAP cut progression/death risk by 37%
🔍 Strongest benefit in BRCA-mutated cases
🔗 bit.ly/ONCOnews4J-7
#OncoAlert #OncEd #ONCOnews #ProstateCancer
June 4, 2025 at 11:56 AM
✨ #ASCO25 ✨
🚨BREAKING:
AMPLITUDE: First Phase 3 trial to show improved rPFS in HRR-altered mCSPC with PARP + AR-pathway inhibitor combo
🧬 Niraparib + AAP cut progression/death risk by 37%
🔍 Strongest benefit in BRCA-mutated cases
🔗 bit.ly/ONCOnews4J-7
#OncoAlert #OncEd #ONCOnews #ProstateCancer
🚨BREAKING:
AMPLITUDE: First Phase 3 trial to show improved rPFS in HRR-altered mCSPC with PARP + AR-pathway inhibitor combo
🧬 Niraparib + AAP cut progression/death risk by 37%
🔍 Strongest benefit in BRCA-mutated cases
🔗 bit.ly/ONCOnews4J-7
#OncoAlert #OncEd #ONCOnews #ProstateCancer
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC @emoryuniversity.bsky.social @winshipcancer.emory.edu #pcsm #oncology
www.onclive.com/view/real-wo...
www.onclive.com/view/real-wo...
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses a retrospective analysis of patients receiving apalutamide vs darolutamide for metastatic castration-sensitive prostate cancer.
www.onclive.com
February 10, 2026 at 10:56 PM
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC @emoryuniversity.bsky.social @winshipcancer.emory.edu #pcsm #oncology
www.onclive.com/view/real-wo...
www.onclive.com/view/real-wo...
How Shared Clinical Decision-Making Can Shape the Metastatic Prostate Cancer Journey www.fiercehealthcare.com/sponsored/ho...
How Shared Clinical Decision-Making Can Shape the Metastatic Prostate Cancer Journey
By Benjamin Lowentritt, MD | When a patient learns they have metastatic castration-sensitive prostate cancer (mCSPC), it often marks the beginning of a long and uncertain journey. The first conversat...
www.fiercehealthcare.com
August 28, 2026 at 11:50 PM
How Shared Clinical Decision-Making Can Shape the Metastatic Prostate Cancer Journey www.fiercehealthcare.com/sponsored/ho...